Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is
accelerating. This analysis summarizes the data derived from the clinical trials conducted at …

Antibody–drug conjugates (ADCs) are immunoconjugates comprised of a monoclonal
antibody tethered to a cytotoxic drug (known as the payload) via a chemical linker. The ADC …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

Background The outcome of older patients with B-cell acute lymphocytic leukaemia is
inferior to that in younger patients due to the adverse disease biology and their inability to …

Background Inotuzumab ozogamicin (InO) is an antibody‐drug conjugate used for adults
with relapsed/refractory B‐cell precursor (BCP) acute lymphoblastic leukemia (ALL). The …

PURPOSE Children's Oncology Group trial AALL1621 was conducted to prospectively
determine the safety and efficacy of inotuzumab ozogamicin (InO) in pediatric and …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

PURPOSE Despite recent advances in adapting the intensity of treatment for older patients
with ALL, current protocols are associated with high rates of early deaths, treatment-related …

Recent years have witnessed major advances that have improved outcome of adults with
acute lymphoblastic leukemia (ALL). The emergence of the concept of measurable residual …